Physician profile
Jun Chen
NPI 1477583763
$2,561.01
in general payments reported to CMS, 2019-2025
23 companies · $905 in 2025
The $905 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $11.25 · 2021: $194 · 2022: $269 · 2023: $319 · 2024: $742 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,875 · Education: $90.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,875.12 |
| Education | $90.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $247.81 | 2019-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $237.89 | 2019-2025 | Jynarque, Voyxact |
| Mallinckrodt Hospital Products INC. | $216.33 | 2024-2025 | Acthar |
| Bayer Healthcare Pharmaceuticals INC. | $186.28 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $174.77 | 2023-2025 | |
| Calliditas Therapeutics US INC. | $172.85 | 2023-2024 | Tarpeyo |
| Astrazeneca Pharmaceuticals Lp | $166.64 | 2020-2025 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $150.35 | 2019-2025 | Rayaldee |
| Scpharmaceuticals INC. | $141.51 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.73 | 2021-2022 | |
| Travere Therapeutics, INC. | $126.46 | 2023-2025 | |
| Glaxosmithkline, LLC. | $111.71 | 2022 | |
| Ardelyx, INC. | $109.09 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Aurinia Pharma U.S., INC. | $83.35 | 2023-2025 | Lupkynis |
| Fresenius USA Marketing, INC. | $78.28 | 2024-2025 | Velphoro, Velphoro |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $73.92 | 2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.00 | 2024-2025 | Jardiance |
| Lilly USA, LLC | $31.11 | 2023-2025 | Jardiance |
| Novo Nordisk INC | $24.30 | 2025 | Ozempic |
| Recor Medical INC | $17.86 | 2025 | Paradise Ultrasound Renal Denervation System |
| Alnylam Pharmaceuticals INC. | $17.74 | 2025 | Givlaari |
| Janssen Pharmaceuticals, INC | $14.76 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $14.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jun Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.